Corticosteroid use in childhood-onset systemic lupus erythematosus - Practice patterns at four pediatric rheumatology centers

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 155-162

  Brunner, Hermine I ^a   Klein Gitelman, Marisa S ^b   Ying, Jun ^a   Tucker, Lori B ^c   Silverman, Earl D ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c BC CHILDREN S HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Children; Corticosteroids; Prednisone; SLE; Treatment patterns

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADOLESCENT; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; PRESCRIPTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; CANADA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 63049092023     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. ARDOIN SP, SCHANBERG LE: The management of pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol 2005; 1: 82-92.
2. BRUNNER HI, SILVERMAN ED, TO T, BOMBARDIER C, FELDMAN BM: Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-44.
3. BRUNNER HI, GLADMAN DD, IBANEZ D, UROWITZ MD, SILVERMAN ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556-62.
4. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
5. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
6. LIANG MH, FORTIN PR, ISENBERG DA, SNAITH L: Quantitative clinical assessment of disease activity in systemic lupus erythematosus: Progress report and research agenda. Rheumatol Int 1991; 11: 133-6.
7. LIANG MH, SOCHER SA, LARSON MG, SCHUR PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
8. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-6.
9. SEARLE SR, CASELLA G, MCCULLOCH CE: Variance components. Hoboken, NJ: Wiley; 2006.
10. HELLMANN DB, PETRI M, WHITING-O'KEEFE Q: Fatal infections in systemic lupus erythematosus: The role of opportunistic organisms. Medicine (Baltimore) 1987; 66: 341-8.
11. ZONANA-NACACH A, BARR SG, MAGDER LS, PETRI M: Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-8.
12. CHATHAM WW, KIMBERLY RP: Treatment of lupus with corticosteroids. Lupus. 2001; 10: 140-7.
13. LEHMAN TJ: Current concepts in immunosuppressive drug therapy of systemic lupus erythematosus. J Rheumatol 1992; 33 (Suppl.): 20-2.
14. MOK CC, HO CT, SIU YP et al.: Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001; 38: 256-64.
15. FAGUNDUS DM, LEROY EC: Lupus and its management. JSC Med Assoc 1993; 89: 516-24.
16. BRUNNER H, JONES O, LOVELL D, TOMASI A, KLEIN-GITELMAN M: Lupus headaches (LHA) and their impact on disease activity measured by the SLEDAI and the prediction of damage in juvenile systemic lupus erythematosus (jSLE). Paper presented at: AMERICAN COLLEGE OF RHEUMATOLOGY CONFERENCE, 2001, San Francisco.
17. BRUNNER H, SILVERMAN E, TO T, BOMBARDIER C, FELDMAN BM: Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 45: 436-44.
18. DORIA A, SHOENFELD Y, WU R et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-7.
19. GLADMAN DD, UROWITZ MB, RAHMAN P, IBANEZ D, TAM LS: Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-9.
20. DOVIO A, PERAZZOLO L, OSELLA G et al.: Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004; 89: 4923-8.
21. HAUGEBERG G, GRIFFITHS B, SOKOLL KB, EMERY P: Bone loss in patients treated with pulses of methylprednisolone is not negligible: A short term prospective observational study. Ann Rheum Dis 2004; 63: 940-4.
22. BUTTGEREIT F, STRAUB RH, WEHLING M, BURMESTER GR: Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action. Arthritis Rheum 2004; 50: 3408-17.
23. ACR: Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: Report of a consensus meeting. Arthritis Rheum 2004; 50: 3427-31.
24. ABRAHAMOWICZ M, FORTIN PR, DU BERGER R, NAYAK V, NEVILLE C, LIANG MH: The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials. J Rheumatol 1998; 25: 277-84.
25. NECELA BM, CIDLOWSKI JA: Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 2004; 1: 239-46.
26. RHEN T, CIDLOWSKI JA: Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.